朱怡莲 杜鹏

    摘 要 自20世纪90年代面世以来，众多研究已经证实，生物制剂治疗急性重度/难治性溃疡性结肠炎可快速诱导缓解、延缓疾病进展。随着众多不同作用机制的生物制剂的上市和应用，溃疡性结肠炎的结肠切除手术率有所下降。在生物制剂时代，溃疡性结肠炎的外科治疗的时机与临床策略均已出现相应的改变。然而，在溃疡性结肠炎患者的长期炎症病程中，对炎-癌转化、疾病急性重度爆发等情况，外科治疗依然具有重要作用。本文探讨在生物制剂时代溃疡性结肠炎外科治疗所面临的挑战及临床价值。

    关键词 溃疡性结肠炎 生物制剂 外科治疗

    中图分类号：R656.6 文献标志码：A 文章编号：1006-1533(2021)11-0019-05

    Surgical treatment of ulcerative colitis in the era of biologics*

    ZHU Yilian1， 2， DU Peng1， 2**

    (1. Department of Colorectal Surgery， Xinhua Hospital； 2. Diagnosis and Treatment Center for Colorectal Cancer， Shanghai Jiao Tong University School of Medicine， Shanghai 200092， China)

    ABSTRACT Since the 1990s， biologics has achieved great success in inducing rapid remission and delaying disease progression in moderate to severe and corticosteroids-dependent ulcerative colitis. A decrease in relevant surgery was observed as more biologics with different mechanisms were applied to clinical practice. In the new era， the timing and clinical strategies for surgical treatment of ulcerative colitis have changed accordingly. However， in the long-term inflammatory course of patients with ulcerative colitis ......